Tamoxifen response in breast cancer predicted by protein marker
the ONA take:
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment, according to a study published in Cancer Research.
“Our data indicate that TGFBR2, which detects TGF-beta and thereby activates subsequent cellular responses, could be used as a marker in the clinics to identify patient subgroups that may not benefit from hormone therapy alone and may require additional therapies,” said author Susann Busch, PhD, of Gothenburg University.
Dr. Busch and colleagues analyzed tumor samples of 564 pre-menopausal women who were enrolled in clinical trials from 1986 to 1991 and randomly assigned to either tamoxifen for two years (276) or no systemic treatment (288).
They found that among women who received tamoxifen and had estrogen receptor-positive tumors, those who had low TGFBR2 levels had a 73 percent lower recurrence-free survival rate compared to those with high levels of the protein.
In a follow-up series of laboratory experiments, the same researchers found that, in a drug-resistant cell line, there were low levels of TGFBR2 and abnormal pathway activation.
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|